MISSION^® Application Data

We are committed to providing you with helpful application notes and data for the MISSION^® TRC shRNA libraries. Below are links to data pieces and articles on various topics of interest. If you would like us to post your data (specific applications, validation of gene targets, etc.) on our site, please send us your experimental summary and data by e-mail.

Posters – MISSION^® R&D

• A Screen of MISSION^® shRNAs Targeting Tumor Suppressor Genes to Identify Factors Involved in A549 Paclitaxel Sensitivity
• Gene Silencing in Primary Astrocyte Cells using MISSION^® TRC shRNA Lentiviral Particles (338 Kb PDF)
• Reproducible, Long-term Silencing in a High-throughput Lentiviral shRNA Screen (211 Kb PDF)
• Verification of RNA Interference at the Protein Level via Quantitative Proteomics Analysis (374 Kb PDF)
• Examination of Efficacy, Specificity, and Efficiency of an shRNA Lentiviral Library (357 Kb PDF)
• Efficient Gene Silencing with High Selectivity using MISSION^® TRC shRNA Lentiviral Vectors

Posters – External Researchers

• Lentiviral shRNA Screen of Multidrug Resistant Associated Genes Identifies PRP-4 as a New Regulator of Chemoresistance in Human Ovarian Cancer (635 Kb PDF)
  Zhenfeng Duan, M.D. Ph.D. – Harvard Medical School
  
  
• shRNA Phenotypic Screen To Identify Gene Targets Contributing to Androgen Independent Prostate Cancer Cell Growth (989 Kb PDF)
  Daniel Gioeli Ph.D. – University of Virginia
  
  
• Mesenchymal Stem Cells: Cell Death or Survival? Interaction with Other Stress Pathways (887 Kb PDF)
  by Oliver L. and Vallette FM, Center for Cancer Research Nantes - Angers INSERM UMR 892, University of Nantes, France

Selected Data Figures
Data type	Format	Gene Targets	Cell Lines	Detection Level	Provided by
Lentivirus is stable after 2.5 years	Viral Particles	N/A	A549	Phenotypic	Our internal operations
Long Term, up to 1 yr, Gene Silencing with shRNA	Viral Particles	ARGHDIA	A549	mRNA	Our internal R&D
Gene Target Validation	Viral Particles, Transduction	CDH1	Human colorectal cancer cell line (coll5)	Protein	Elena Sancho, PhD and Eduard Batlle, PhD Barcelona Institute for Research in Biomedicine
Stable Cell Line/ Signaling Pathway	Viral Particles, Transduction	ZFP36 (TTP)	A549	mRNA & Protein	Kathleen Smoak, PhD and John A Cidlowski, PhD Laboratory of Signal Transduction, National Institute of Environmental Health Services, National Institutes of Health
Efficacy, Specificity and Efficiency	Viral Particles, Transduction	p38α, p38γ, JNK2, MAP3K4, JAK1, AKT1, AKT2, AKT3	Primary human astrocytes, A549, HepG2, HCT116, Panc1, HeLa	mRNA	Our internal R&D
Primary Astrocyte Cells (Neuronal Cells)	Viral Particles, Transduction	p38α, p38γ, JNK2, MAP3K4	Primary human astrocytes	mRNA	Our internal R&D
Specificity in Targeting Isoforms	Viral Particles, Transduction	AKT1, AKT2, AKT3	A549	mRNA	Our internal R&D
Gene Target Validation	Viral Particles, Transduction	c-MYC	Human lung cancer cell line (H1299)	mRNA & Protein	Steven B. McMahon, Ph.D. The Wistar Institute
Demonstration of 3' UTR Utility, Knockdown of Overexpressed Protein	Plasmid, Transfection	FBXO6	COS-7	Protein	Kevin Glenn, M.D. Carver College of Medicine, University of Iowa
Efficiency of MISSION® TurboGFP™ Transduction Control	Viral Particles, Transduction	N/A	Primary BJ Fibroblasts	Protein (FACS)	Sheila Stewart, Ph.D. Washington University
Interferon Response	Viral Particles, Transduction	CSK, AUR/KB, TYK2, YES1, AKT3	HT29	mRNA	Cell, 124, pp. 1283-1298. 20061
Stability of pLKO.1-puro	Plasmid DNA	N/A	N/A	Restriction Digest	Cell, 124, pp. 1283-1298. 20061
Dose-Response	Viral Particles, Transduction	HCK, PDGFRB, TIE1, BCR, YES1, MAP2K4, PTK7, KIS, PRKACB, MAK	HT29	Cell Viability, Mitotic Index	Cell, 124, pp. 1283-1298. 20061
Efficacy in Cell Types	Viral Particles, Transduction	N/A	See Table	N/A	Compilation
High-Throughput Gene Target Validation	Viral Particles, Transduction	60 Different Targets	A549	mRNA	Our internal R&D
High-Throughput Screening	Viral Particles, Transduction	Human Tumor Suppressor Gene Family Set	A549	Cell Viability Assay	Our internal R&D
High-Throughput Lentiviral Particle Production	Viral Particles	6000+ individual clones	N/A	p24 Assay	Our internal operations

Publications

1. Duan Z, Weinstein EJ, Ji D, Ames RY, Choy E, Mankin H, Hornicek FJ. 2008. Lentiviral short hairpin RNA screen of genes associated with multidrug resistance identifies PRP-4 as a new regulator of chemoresistance in human ovarian cancer. Mol Cancer Ther. 7(8):2377-2385. https://doi.org/10.1158/1535-7163.mct-08-0316

2. Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA. 2010. RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Res. 12(3): https://doi.org/10.1186/bcr2595

3. Moffat J, Grueneberg DA, Yang X, Kim SY, Kloepfer AM, Hinkle G, Piqani B, Eisenhaure TM, Luo B, Grenier JK, et al. 2006. A Lentiviral RNAi Library for Human and Mouse Genes Applied to an Arrayed Viral High-Content Screen. Cell. 124(6):1283-1298. https://doi.org/10.1016/j.cell.2006.01.040